Jennifer Michaelson Sells 3,601 Shares of Cullinan Therapeutics (NASDAQ:CGEM) Stock

Posted by Lindsey Winhoffer on Feb 27th, 2026

Cullinan Therapeutics, Inc. (NASDAQ:CGEM – Get Free Report) insider Jennifer Michaelson sold 3,601 shares of Cullinan Therapeutics stock in a transaction that occurred on Tuesday, February 24th. The shares were sold at an average price of $14.47, for a total transaction of $52,106.47. Following the sale, the insider directly owned 176,624 shares of the company’s stock, valued at $2,555,749.28. This represents a 2.00% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink.

Jennifer Michaelson also recently made the following trade(s):

On Wednesday, February 25th, Jennifer Michaelson sold 1,780 shares of Cullinan Therapeutics stock. The stock was sold at an average price of $14.14, for a total value of $25,169.20.
On Monday, February 23rd, Jennifer Michaelson sold 1,752 shares of Cullinan Therapeutics stock. The shares were sold at an average price of $13.99, for a total value of $24,510.48.
On Friday, February 20th, Jennifer Michaelson sold 11,742 shares of Cullinan Therapeutics stock. The shares were sold at an average price of $14.08, for a total value of $165,327.36.
On Thursday, February 12th, Jennifer Michaelson sold 416 shares of Cullinan Therapeutics stock. The stock was sold at an average price of $12.03, for a total transaction of $5,004.48.
On Thursday, January 22nd, Jennifer Michaelson sold 4,000 shares of Cullinan Therapeutics stock. The stock was sold at an average price of $12.30, for a total transaction of $49,200.00.
On Friday, December 19th, Jennifer Michaelson sold 1,345 shares of Cullinan Therapeutics stock. The shares were sold at an average price of $10.01, for a total transaction of $13,463.45.
On Thursday, December 18th, Jennifer Michaelson sold 2,898 shares of Cullinan Therapeutics stock. The stock was sold at an average price of $9.67, for a total transaction of $28,023.66.
On Monday, December 15th, Jennifer Michaelson sold 995 shares of Cullinan Therapeutics stock. The shares were sold at an average price of $11.90, for a total transaction of $11,840.50.
On Friday, December 12th, Jennifer Michaelson sold 2,148 shares of Cullinan Therapeutics stock. The stock was sold at an average price of $12.38, for a total transaction of $26,592.24.

Cullinan Therapeutics Stock Up 5.9%

Cullinan Therapeutics stock opened at $15.21 on Friday. The firm has a market cap of $898.61 million, a P/E ratio of -4.60 and a beta of -0.09. The business has a fifty day moving average of $11.61 and a two-hundred day moving average of $9.35. Cullinan Therapeutics, Inc. has a twelve month low of $5.68 and a twelve month high of $15.23.

Institutional Trading of Cullinan Therapeutics

A number of institutional investors have recently bought and sold shares of the stock. Seven Fleet Capital Management LP acquired a new position in Cullinan Therapeutics during the 4th quarter valued at approximately $31,000. Invesco Ltd. grew its holdings in shares of Cullinan Therapeutics by 27.4% during the fourth quarter. Invesco Ltd. now owns 130,323 shares of the company’s stock valued at $1,349,000 after buying an additional 28,011 shares during the last quarter. Virtus Investment Advisers LLC increased its position in shares of Cullinan Therapeutics by 75.5% in the 4th quarter. Virtus Investment Advisers LLC now owns 22,318 shares of the company’s stock valued at $231,000 after acquiring an additional 9,604 shares during the period. Susquehanna Portfolio Strategies LLC raised its stake in Cullinan Therapeutics by 87.8% in the 4th quarter. Susquehanna Portfolio Strategies LLC now owns 233,842 shares of the company’s stock worth $2,420,000 after acquiring an additional 109,311 shares during the last quarter. Finally, Elmind Capital LP acquired a new stake in Cullinan Therapeutics during the 4th quarter worth about $3,208,000. 86.31% of the stock is currently owned by institutional investors and hedge funds.

Key Cullinan Therapeutics News

Here are the key news stories impacting Cullinan Therapeutics this week:

Positive Sentiment: Near-zero reported short interest reduces potential forced selling and can limit downside pressure, supporting the stock’s move higher. Short Interest Report
Positive Sentiment: Analyst coverage is tilted positive: several firms (Guggenheim, Citi, HC Wainwright) carry Buy ratings and materially higher price targets than the current quote, creating an upside narrative that can attract buyers. Analyst Coverage
Positive Sentiment: Institutional investors increased positions in Q4 (Invesco, Virtus, Susquehanna and others reported larger stakes), which can provide buying support and signal conviction from larger market participants. Institutional Activity
Neutral Sentiment: Market context: broader risk-on/risk-off swings (crypto weakness noted in recent headlines) can affect small-cap biotechs indiscriminately; this is a macro factor rather than company-specific news. Macro/Crypto Headline
Neutral Sentiment: Some shops have trimmed ratings recently (a few downgrades), creating dispersion in expectations—this can increase volatility but does not decisively change the bullish analyst narrative. Analyst Notes
Negative Sentiment: Multiple senior insiders sold sizable blocks on Feb. 24–25, including CEO Nadim Ahmed (13,515 shares) and other executives—clustered insider sales can be perceived as insider monetization and pressure sentiment. CEO Sale Filing
Negative Sentiment: Director/executive Jennifer Michaelson executed multiple recent sales (Feb. 23–25 series of transactions), further trimming insider holdings and amplifying concerns about insider cash-outs. Insider Trades Summary

Wall Street Analyst Weigh In

Several research firms have issued reports on CGEM. HC Wainwright lifted their target price on Cullinan Therapeutics from $26.00 to $27.00 and gave the company a “buy” rating in a research note on Thursday, January 8th. Wedbush boosted their price objective on shares of Cullinan Therapeutics from $25.00 to $34.00 and gave the stock an “outperform” rating in a research note on Tuesday, December 9th. New Street Research set a $26.00 target price on shares of Cullinan Therapeutics in a research report on Thursday, November 20th. Guggenheim initiated coverage on shares of Cullinan Therapeutics in a report on Monday, February 2nd. They issued a “buy” rating and a $30.00 price target on the stock. Finally, BTIG Research upped their price target on Cullinan Therapeutics from $32.00 to $38.00 and gave the stock a “buy” rating in a research report on Monday, November 24th. Eight research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Cullinan Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $29.33.

Check Out Our Latest Research Report on CGEM

About Cullinan Therapeutics

(Get Free Report)

Cullinan Therapeutics, Inc, a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer.